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Abstract
The objective of the present investigation was to study the effect of presence of choline dichloride (CDC) in 
β-cyclodextrin (β-CD) on in vitro dissolution of Ursodeoxycholic acid (UDCA) from molecular inclusion complexes. 
The molecular inclusion complexes of UDCA with β-CD coprecipitated with CDC were prepared using kneading 
method. In vitro dissolution of pure drug, physical mixtures and cyclodextrin inclusion complexes (UDCA-β-CD-
CDC) were carried out. Molecular inclusion complexes of Ursodeoxycholic acid with coprecipitated β-CD showed 
considerable increase in the dissolution rate in comparison with physical mixture and pure drug in 0.1 N HCl, pH1.2 
and phosphate buffer, pH 7.4. Inclusion complexes with 1:2M ratio showed maximum dissolution rate in comparison 
to other ratios. FT-IR spectroscopy and differential scanning calorimetry studies indicated no interaction between 
UDCA and β-CD-CDC in complexes in solid state. Dissolution enhancement was attributed to the formation of water 
soluble inclusion complexes with the precipitated form of β-CD. The in vitro release from all the formulations was best 
described by first order kinetics followed by Higuchi release model. In conclusion, dissolution of Ursodeoxycholic 
acid can be enhanced by using the β-CD-CDC coprecipitate as a host molecule. 
Keywords:  Ursodeoxycholic acid;β-CD;  CDC;solubility;complexes
Introduction
Up to 40 percent of new chemical entities discovered by the 
pharmaceutical industry today are poorly soluble or lipophilic 
compounds [1]. The solubility issues complicating the delivery of these 
new drugs also affect the delivery of many existing drugs. Poorly water-
soluble drugs show unpredictable absorption, since their bioavailability 
depends upon dissolution in the gastrointestinal tract [2-4]. The 
dissolution characteristics of poorly soluble drugs can be enhanced 
by several methods [5–7]. Cyclodextrin and their derivatives play 
an important role in formulation development due to their effect on 
solubility, dissolution rate, chemical stability and absorption of drugs. 
Though cyclodextrins have been investigated widely during the last two 
decades, their commercial application in pharmaceutical formulation 
was started only in recent years with drugs such as piroxicam and 
nimesulide [8].  
Ursodeoxycholic acid (UDCA) (Figure 1) is a white, odorless, 
crystalline powder with a bitter taste. Chemically it is 3α, 7β-dihydroxy-
5-cholan-24-oic acid. It is a water insoluble drug used as a drug for the 
dissolution of cholesterol gallstones because it reduces the cholesterol 
saturation of bile [9-11]. The use of UDCA for the treatment of other 
liver diseases, such as primary biliary cirrhosis, chronic hepatitis 
and biliary pains has been demonstrated [12-14]. However in vivo 
studies have shown that intestinal absorption and consequently the 
bioavailability of the drug are generally poor and erratic both among 
different subjects, and within the same subject. More than 50% is lost 
in the stool after a single oral dose of 300 mg.
The possibility to increase the complexing ability of β-CD by their 
prior coprecipitation with molecules like choline dichloride able to 
increase the aqueous solubility of lipophilic drugs seemed to represent 
a further approach to the utilization of β-CD as aqueous solubility and 
therefore attempt has been made to prepare inclusion complexes of 
Ursodeoxycholic acid with coprecipitated β-cyclodextrin (β-CD) with 
an aim to improve its extent and rate of dissolution. 
Material and Methods
Ursodeoxycholic acid (Lab. Chem. Sdn. Bhd., Malaysia), 
β-cyclodextrin (β-CD) (Himedia Laboratories Limited, Mumbai) of 
commercial purity grade were used. All other chemicals used were of 
analytical reagent grade. 
Figure 1: Ursodeoxycholic acid.
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Preparation of β-CD- Choline Dichloride (β-CD-CDC) 
Coprecipitate
β-CD (10 g; 8.81 mmol) was dissolved in 100 ml of DMSO. CDC 
(1.4 g; 8.81 mmol) was added. The solution was stirred for 24 h at 50º 
C. After this period a di-ethyl ether-acetone (2:1 v/v) mixture was 
added to the solution to induce coprecipitation of β-CD and CDC. The 
precipitate obtained was subsequently washed first with the diethyl 
ether-acetone mixture and subsequently with diethyl ether and dried 
under vaccum [15].
Preparation of Physical Mixtures
The physical mixtures were prepared by manually mixing pre 
weighed amounts of mesh. No 100-sieve fractions of UDCA, β-CD and 
CDC [16]. The mixing was performed adopting the geometric dilution 
method.
Preparation of Molecular Inclusion Complexes 
Solid inclusion complexes of UDCA with β-CD-CDC were prepared 
in 1:1 and 1:2 molar ratios using kneading method. Accurately weighed 
quantity of β-CD-CDC was taken in a glass mortar; water was added 
slowly and mixed to obtain a homogeneous paste. Weighed quantity 
of UDCA was added slowly by grinding. The mixture was ground for 
one hour. During this process appropriate quantity of water was added 
to maintain suitable consistency. The obtained solid mass was further 
dried under vaccum to a constant weight at room temperature and 
pulverized, sieved through mesh # 100 and stored in dessicator [15,16]. 
Phase Solubility Studies 
The phase solubility studies were performed according to the 
method reported by Higuchi and Connors [17,22]. Excess amount of 
UDCA (50 mg)  was added to 25 ml of  aqueous solution (pH 7.0) 
containing various concentrations of β-CD (1-15 mM ) in a series of 
stoppered conical flask and the mixtures were shaken at 30°C for 24 
h at room temperature on a rotary flask shaker. After equilibration, 
the solutions were filtered immediately using 0.5µ nylon disk filter. 
The filtered samples were suitably diluted and assayed for drug content 
using HPLC method [18]. Shaking of aqueous solutions of drugs and 
β-CD were continued until the three consecutive estimations were 
same. The apparent stability constant (Kc), according to the hypothesis 
of 1:1 stoichiometric ratio of the complexes was calculated from the 






                                                               (1) 
 
The values of Kc indicated the stability of the drug-β-CD complexes. 
The solubility experiments were conducted in triplicate. 
Characterisation of Molecular Inclusion Complexes
Percent yield: The percent yield of molecular inclusion complexes 
was calculated on the basis of dry weight (drug and carriers) and the 
final weight of molecular inclusion complexes was obtained [19].
100
Dry weight of the product
Percent yield
Dry weight of the drug and polymers
= ×  (2)
Average particle size: The molecular inclusion complexes were 
dispersed in liquid paraffin and mounted on slides.  Particle size of 200 
particles was measured using calibrated stage micrometer and ocular 
micrometer. From the data the average particle size was calculated [19]. 
Hygroscopic studies: The molecular inclusion complexes were 
dried in a dessicator under anhydrous calcium chloride for two days. 
One hundred mg each of molecular inclusion complexes (w1) was 
placed on a watch glass and exposed to ambient atmospheric conditions 
(70±5% RH, 30±2°C) and saturation humidity conditions (99±1% RH, 
30±2°C) for 2 days. The substance was weighed again (w2). The gain in 
the weight was determined and the percentage moisture gained was 
calculated, using the below given equation [20].
( )2 1
1





= ×                (3) 
Drug content: Content of UDCA in molecular inclusion complexes 
was estimated using HPLC method.
Scanning electron microscopy 
Scanning Electron Microscopy (SEM) was carried out for 1:1 
molecular inclusion complexes. The surface morphology of the selected 
binary systems was studied using a Phillips 1500, scanning electron 
microscope (JSM-840, JEOL, Japan). The powders were previously 
fixed on a brass stub using double sided adhesive tape and then were 
made electrically conductive by coating in vaccum, with a thin layer 
of gold (approximately 300 Å), for 30s and at 30 W. The micrographs 
were taken at an excitation voltage of 15 KV and a magnification of 750 
or 5000 X [20].
Fourier transformed infrared spectroscopic studies 
Fourier transformed infrared (FTIR) spectra were routinely 
obtained to assess the drug-carrier interaction using Shimadzu FTIR-
8400S Fourier transform infrared spectrophotometer. FTIR spectral 
studies were carried out for pure drug, freshly prepared and six months 
old 1:1 molecular inclusion complexes and individual substances to 
check the compatibility between drug and carriers. Interaction between 
the components, if any, was indicated by either producing additional 
peaks or absence of the characteristic peaks corresponding to the drug 
and carrier [21,26]. 
Differential scanning calorimetric studies 
Differential scanning calorimetric (DSC) studies were carried 
to check the compatibility between drug and carriers.  DSC studies 
were carried out for pure drug, freshly prepared and six months old 
1:1 molecular inclusion complexes. All dynamic DSC studies were 
carried out on a calibrated Shimadzu DSC-50 Thermal Analyzer. 
Calorimetric measurements were made with empty cell (high purity 
alpha alumina discs as reference). The dynamic scans were taken in 
nitrogen atmosphere at the heating rate of 10°C/minute. Interaction 
between the drug and polymer, if any, was indicated either by a shift 
in the peak or presence of additional peaks at temperatures other than 
those corresponding to the drug and carrier [21,23].
X-Ray diffractometry 
The physical state of pure drug, freshly prepared and six months 
old 1:1 molecular inclusion complexes. was evaluated by X-ray 
diffraction (X-RD). Powder X-RD was carried out with the Philips 
X-ray diffractometer (PW 1050/PW 1710) using Ni-filtered, CuKα 
radiation (I= 1.5418 Å), a voltage of 40kV and a current of 40mA. The 
scanning rate was 6 °/min over a 2θ range of 5-50°, chart speed 10mm/
min and count range 1000 cps [23,24,26].
In vitro release studies 
In vitro release studies were carried out using basket type USP XXII 
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dissolution test apparatus [18].  Release studies were carried separately 
for pure drug, physical mixtures and molecular inclusion complexes 
of UDCA 2h. Pure drug (100 mg) and formulations containing drug 
content equivalent to 100 mg of UDCA was separately studied for in 
vitro release. Dissolution was carried out in 900 ml of 0.1 N hydrochloric 
acid solution, pH 1.2 and phosphate buffer, pH 7.4 separately, with a 
stirring speed of 50 rpm at a temperature of 37±0.5°C. Five ml aliquots 
of dissolution medium were withdrawn at an interval of 5 minutes for 
first 15 minutes and then 15 minutes intervals, for rest of the two-hour 
study and filtered through a 0.45µ filter. The volume withdrawn at each 
time was replaced with an equal volume of pre-warmed dissolution 
medium. The drug content was estimated using the HPLC method. The 
dissolution experiments were conducted in triplicate [24,25].
Kinetic analysis of drug release
The dissolution profiles of all the molecular inclusion complexes 
were subjected to the kinetic analysis to establish the drug-release 
mechanism. The release data were fitted to zero order (Equation 4), first 
order (Equation 5), matrix (Higuchi model) (Equation 6) and Hixson-
Crowell equations (Equation 7) to ascertain the kinetic modeling of 
drug release [24].  
Qt = k0t                                                                    (4)
ln Qt = ln Q0 - k1t                                                                    (5)
Qt = kHt
1/2                                                                                                                  (6)
Q0
1/3 – Qt1/3 = kHCt                                                                       (7)
Where Qt is the amount of drug released at time t, Q0 is the initial 
amount of drug in the formulation and k0, k1, kH & kHC are release rate 
constants for zero-order, first-order, Higuchi model and Hixson-
Crowell rate equation [27-29].
Result and Discussion
Phase solubility studies
Phase solubility studies of UDCA--CD systems in water at 25°C 
revealed that the solubility of UDCA increased linearly with the 
increase in the concentration of β-CD, showing a typical AL -type 
phase solubility curve. Since the slope of the phase solubility curve 
was < 1 for UDCA, the increase in solubility was due to the formation 
of stoichiometric 1:1M complex in solution with β-CD. The apparent 
stability constant (Kc) was calculated from the slope of the linear plot of 
the phase solubility diagram and was found to be 479.14 M-1. 
Characterisation of molecular inclusion complexes of 
usrodeoxycholic acid
All the UDCA -β-CD-CDC molecular inclusion complexes 
prepared were found to be fine and free flowing powders.
Percent yield: As indicated in Table 1 the percentage yield ranged 
from 85.2 to 88.3 % for the β-CD molecular inclusion complexes. 
Low coefficient of variance (CV) values (< 1.0 %) in percentage 
yield indicates the reproducibility of the technique employed for the 
preparation of molecular inclusion complexes.
Average particle size: Average particle size was found to be within 
the range of 56.2 µm to 77.5µm (Table 1). This narrow range of particle 
size was satisfactory from the point of improving the aqueous solubility. 
Drug content: The percentage entrapment of the drug in 
molecular inclusion complexes was found to be approximately nearer 
to the theoretical values (Table 1). Low value for CV (<1.0) indicates 
uniformity of drug content in the product. The obtained results implied 
that the drug remained stable during preparation.
Hygroscopic Studies: Results for the percent weight gain by β-CD 
complexes are shown in Table 2. The hygroscopicity of binary system 
containing UDCA -β-CD-CDC in 1:2M ratio was found to be more 
Product Drug : carrier Percent yield Particle size range (µm)
Average particle size  
(µm)
Drug content     
(mg) Percent drug content
UDCA-βCD-CDC1  1 : 1M 85.2(0.79) 5.3-137.5 56.2 (0.45) 31.5 (33)* 95.4 (0.82)
UDCA-βCD-CDC2 1 : 2M 88.3 (0.84) 6.2-134.3 77.5 (0.18) 48.1 (50)* 96.0 (0.89)
UDCA: Ursodeoxycholic acid; CDC: choline dichloride; β-CD: β-cyclodextrin; M: molar. Values in parenthesis indicates the standard deviation (n=3) and values given in 
the parenthesis marked with * indicates theoretical values of drug content.
Table 1: Physical characteristics of molecular inclusion complexes of Ursodeoxycholic acid.
Figure 2: Scanning electron photomicrographs of ursodeoxycholic acid (A); β-cyclodextrin (B); UDCA- β-CD-CDC inclusion complex (1:2 M) (C).
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in comparison with other carriers under ambient as well as saturation 
humidity conditions. Similar results were reported by Sethia and 
Squilante [30] with carbamazepine and Martinez-ohariz et al. [31] with 
diflunisal. 
Scanning electron microscopy: The scanning electron micrographs 
of UDCA molecular inclusion complexes of UDCA are given in 
Figure 2. UDCA appeared as irregular shaped crystals and β-CD has 
shown a parallelogram shape. The original morphology of all other 
binary systems (molecular inclusion complexes) had disappeared and 
it was not possible to differentiate between the two components. All 
the binary systems appeared as agglomerates exhibiting the presence 
of a homogeneous solid phase of amorphous nature. Existence of a 
single phase is also responsible for the enhanced drug dissolution in 
comparison to pure UDCA.
Fourier transformed infrared spectroscopic studies: All the 
characteristic bands of UDCA were observed in the molecular inclusion 
complexes. Broadening of bands was observed to a large extent. The 
characteristic bands of β-CD (3305, 1420, 1460 and 1083 cm-1) were 
Figure 3: FTIR spectra of ursodeoxycholic acid and different β-cyclodextrin-CDC complexes. (A) UDCA; (B) βCD ; (C)  UDCA-βCD-CDC (complex) 1:1 M; (D) UDCA-
βCD-CDC (complex) 1:2M. UDCA= ursodeoxycholic acid; βCD= β-cyclodextrin; CDC= choline dichloride; M= molar.
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Figure 4: DSC thermogram of  (A) UDCA; (B) β-CD; (C) UDCA- β-CD-CDC 1:1M  (complex); (D) UDCA-β-CD-CDC 1:2M (complex). UDCA= ursodeoxycholic acid; 
β-CD= β-cyclodextrin; CDC= choline dichloride; M= molar.
also observed (Figure 3). The FTIR spectra of physical mixtures and 
complexes indicate reduction in the intensity of several peaks like O-H 
(s) and C-H (s). The absence of any significant change in the IR spectral 
pattern in the formulations containing the drug and carriers indicated 
the absence of interaction between the drug and carriers employed for 
the solubility enhancement.
Differential scanning calorimetric studies: The differential scanning 
calorimetric (DSC) thermograms of UDCA, β-CD, CDC, physical 
mixtures and β-cyclodextrin-CDC complexes are given in Figure 3. The 
pure UDCA exhibited endothermic peak at 203°C which represents the 
melting of UDCA and in accordance with the literature value [27]. β-CD 
and CDC showed endothermic peaks at 104°C and 230°C respectively. 
β-CD peak at 104 °C may be attributed to the dehydration process. 
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The DSC curve of UDCA -β-CD-CDC physical mixtures show peaks 
resulting from the superposition of their separated component DSC 
curves. In contrast, disappearance of endothermic peak corresponding 
to UDCA was observed in the DSC curves of UDCA -β-CD-CDC 
complexes. The disappearance of this peak may be probably due to 
Figure 5: XRPD diffractogram of  (A) UDCA; (B) β-CD; (C) UDCA- β-CD-CDC 1:1M  (complex); (D) UDCA-β-CD-CDC 1:2M (complex). UDCA= ursodeoxycholic acid; 
β-CD= β-cyclodextrin; CDC= choline dichloride; M= molar.
the interaction of UDCA with β-CD-CDC and formation of inclusion 
complexes (Figure 4). DSC thermograms indicate the existence of 
the new solid phase and confirm FTIR spectral data concerning the 
presence of UDCA in an amorphous and homogenously dispersed state 
in β-CD-CDC. The DSC further supported that UDCA was compatible 
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with β-CD-CDC system. No additional or shift in endothermic peaks 
were observed which indicated the compatibility between the drug and 
carriers. The findings indicated that the drug was stable in β-CD-CDC 
molecular inclusion complexes prepared freshly and after 6 months 
storage.
X-Ray diffractometry: X-ray diffractometry (X-RD) pattern of 
UDCA, β-CD, CDC, physical mixtures and β-cyclodextrin-CDC 
Figure 6: In vitro dissolution profile of ursodeoxycholic acid-β-CD-CDC 
inclusion complexes and their physical mixtures in 0.1N HCl, pH 1.2.
Figure 7: In vitro dissolution profile of ursodeoxycholic acid-β-CD-CDC 
inclusion complexes and their physical mixtures in phosphate buffer, pH 7.4.
complexes are given in Figure 5.The X-RD pattern of pure UDCA 
showed sharp and characteristic high intensity diffraction peaks at 
2θ values of 9.76, 12.23, 16.12, 20.51, 22.57 and 24.72. The numerous 
diffraction peaks with high intensities in ursodeoxycholic acid its 
existence in a highly crystalline state, while in β-cyclodextrin-CDC 
complexes, X-RD patterns showed a broad diffraction band with 
markedly reduced intensity.The results indicate the existence of UDCA 
in amorphous state and hence showing enhanced aqueous solubility. 
The obtained results are in confirmation with the microscopic studies. 
In vitro release studies: In both, 0.1N HCl (pH 1.2) and phosphate 
buffer (pH 7.4), the physical mixtures and molecular inclusion 
complexes with all UDCA:β-CD-CDC ratios exhibited faster dissolution 
rates than that of pure UDCA at all time points. The dissolution rate of 
β-CD-CDC molecular inclusion complexes was faster as compared to 
their corresponding physical mixtures at all the time intervals (Table 3, 
Figure 6,7). With the increase in the proportion of β-CD-CDC, rate of 
dissolution of molecular inclusion complexes increased.
All the UDCA complexes showed a better dissolution profile in 
phosphate buffer, pH 7.4 in comparison to 0.1N HCl, pH 1.2. The 
drug release from different formulations were ranked as β-CD-CDC 
molecular inclusion complex > physical mixtures > pure drug (UDCA).
It was also found that 1:2 M ratio of UDCA-βCD-CDC showed 
maximum dissolution both in 0.1N HCl, pH 1.2 (64.1±0.95%) and 
phosphate buffer, pH 7.4 (72.3 ±1.30%). The increase in dissolution 
rate is due to the formation of water soluble inclusion complexes with 
the β-CD-CDC. The water molecules in the cavities of β-CD-CDC 
are in an energetically unfavored state because of the apolar nature 
of the cavity. Replacement of high energy water molecules with a 
hydrophobic guest in cavity is therefore favored. The removal of high 
energy molecule out of the cavity by displacement is the driving force 
for the formation of an inclusion complex in aqueous solution. The 
guest molecule is associated with β-CD-CDC by non-covalent and 
weak intermolecular forces. 
The interactions between the hydrophobic part of the guest and the 
apolar cavity causes dehydration of the hydrophobic guest molecule and 
its transfer into the cavity, thereby increasing the affinity towards water 
and hence increasing the dissolution [32]. The surfactant like properties 
of CDs can also be postulated to explain the higher dissolution rate of 
Formulation code Drug: Carrier Initial weight (mg)
Ambient conditions
(70 ± 5% RH, 30 ± 2 C)
Saturation humidity conditions
(99±  2% RH,30 ± 2 C)
Final weight (mg) Percent weight gained        (mg)
Final weight 
(mg)
Percent weight gained 
(mg)
UDCA Pure drug 100 100.3 0.3 (0.17) 101.6 1.6 (0.13)
UDCA-βCD-CDC1  1 : 1M 100 101.3 1.3 (0.15) 103.7 3.7 (0.14)
UDCA-βCD-CDC2 1 : 2M 100 101.5 1.5 (0.13) 107.2 7.2 (0.26)
UDCA: Ursodeoxycholic acid; CDC: choline dichloride; β-CD: β-cyclodextrin; M: molar. Values in parenthesis indicates the standard deviation (n=3)
Table 2: Determination of hygroscopicity of molecular inclusion complexes of ursodeoxycholic acid.
Composition Ratio
Percent drug released after 2 hr
0.1 N HCl, pH 1.2 Phosphate buffer, pH 7.4
UDCA (Pure Drug) 1:0 17.2 (0.91) 20.3 (1.02)
UDCA-βCD-CDC1  (PM) 1:1 21.9 (1.15) 23.3 (1.32)
UDCA-βCD-CDC2 (PM) 1:2 29.3 (0.95) 43.2 (1.49)
UDCA-βCD-CDC1  1:1 41.2  (1.07) 47.4  (0.31)
UDCA-βCD-CDC2 1:2 67.1 (0.92) 76.3 (1.21)
UDCA: ursodeoxycholic acid; β-CD: β-cyclodextrin; CDC: choline dichloride; M: molar; PM: physical mixture. Mean and standard deviation (in parenthesis), n=6
Table 3: In vitro dissolution profile of ursodeoxycholic acid βCD--CDC molecular inclusion complexes in 0.1 N HCl, pH 1.2 and phosphate buffer, pH 7.4.
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the complexes [32]. CDs can also reduce the interfacial tension between 
the solid particles of drug and the dissolution medium, leading to a 
greater rate of dissolution [33]. Increased solubility of physical mixture 
over the pure drug can be attributed to the wetting of hydrophobic 
surface of UDCA due to solubilisation of water-soluble carrier. 
Kinetic analysis of drug release: The kinetics of in vitro release of the 
best formulations of UDCA (UDCA-βCD-CDC 1:2M) was carried out. 
The release of drug from all formulations was observed to follow the 
first order release kinetics, since the correlation coefficient (R2) for first 
order was higher in comparison to zero order release. The results were 
in agreement with the previous investigations performed by Shivkumar 
et al. [34]. A higher correlation, as indicated by R2 was observed for 
the Higuchi matrix release kinetics in all the selected formulations 
suggesting the diffusion as a probable prominent mechanism of drug 
release [35,36]. In diffusion, the rate of dissolution of drug particles 
within the matrix must be much faster than that of the diffusion rate of 
drug leaving the matrix.
Conclusion
The present study clearly shows that addition of β-CD-CDC 
coprecipitate to Ursodeoxycholic acid improves its dissolution rate. 
Further, all the molecular inclusion complexes performed better 
than the corresponding physical mixtures. FT-IR spectroscopy and 
differential scanning calorimetry studies indicated no interaction 
between usrodeoxycholic acid and β-CD-CDC in complexes in solid 
state.  The above studies conclude that complexation of UDCA with 
β-CD lends an ample credence in enhancing its dissolution profile, 
which in turn have potential to produce a faster onset of action and will 
also be helpful in dose reduction. 
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